Vivace Therapeutics

Executive Summary

Vivace Therapeutics is a private, oncology-focused biotech dedicated to developing first-in-class small molecule inhibitors of the Hippo-YAP signaling pathway, a key driver of tumor growth and metastasis. Founded in 2018 and operating with a capital-efficient model leveraging expertise from the US and China, the company's lead asset is VT3989, an oral TEAD inhibitor currently in a Phase 1/2 clinical trial for malignant mesothelioma and other solid tumors. VT3989 has shown early signs of monotherapy activity and a favorable safety profile, positioning it as a potential best-in-class therapy. The company is also advancing a pipeline of next-generation TEAD inhibitors and exploring combination strategies to overcome resistance. With a lean operational structure and a validated target biology, Vivace represents a high-upside opportunity in the precision oncology space, though clinical proof-of-concept remains to be fully established.

Upcoming Catalysts (preview)

• H2 2026VT3989 Phase 1/2 interim efficacy and safety data65% success
• 2027IND filing for next-generation TEAD inhibitor program50% success
• TBDPotential strategic partnership or licensing deal for VT3989 in Asia40% success